Orlance

Executive Summary

Orlance is a Seattle-based biotechnology company pioneering a needle-free epidermal delivery platform for powdered nucleic acid vaccines and immunotherapies. Its MACH-1 technology targets the immunologically active layers of the skin, offering precise, dose-sparing, and thermostable delivery. The lead program is a universal influenza vaccine currently in pre-IND development. Founded in 2020, the company operates in the early clinical stage (Phase 1) and has not publicly disclosed funding or valuation. Orlance's platform has the potential to transform vaccine administration by eliminating needles, improving stability, and enabling self-administration. The universal influenza vaccine addresses a significant unmet need for broad and durable protection. The company's progress is contingent on advancing its lead candidate into clinical trials and securing partnerships or funding to support development.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Universal Influenza Vaccine65% success
• Q2 2026Series A Funding Round Announcement50% success
• Q4 2026Partnership or Collaboration for MACH-1 Platform40% success